MHRA's Four-Year Women's Health Programme Puts FemTech Regulation Under the Microscope
Launched 16 November at the inaugural DIA-MHRA Global Summit, the regulator's 2026-2030 Women's Health Programme exposes a stark clinical-trial gap and sets a timetable that will reshape how drugs, devices and FemTech products are assessed for half the population.

A Data Problem Hiding in Plain Sight
The numbers are hard to argue with. (cite index="44-4">An MHRA analysis of 4,614 UK clinical trial applications submitted between 2019 and 2023 found that pregnant women were represented in just 1.1% of trials, while breastfeeding women accounted for only 0.6%.</cite> (cite index="42-2">In the post-market phase, adverse events disproportionately affect women, and it remains unclear whether this reflects a genuine susceptibility.</cite> Those two sentences together explain why the regulator felt compelled to act.
So they did. (cite index="29-5">The UK Medicines and Healthcare products Regulatory Agency launched its Women's Health Programme on November 16, 2026, setting out a 2026-2030 plan to improve evidence on medicines and medical devices used by women.</cite> (cite index="45-4">The regulator announced the programme at the inaugural DIA-MHRA Global Summit in London, held on 16 and 17 November 2026.</cite>
What the Programme Actually Commits To
(cite index="30-3">The Women's Health Programme aims to ensure women are better represented in clinical research and that the potential risks and benefits of treatments are better understood.</cite> (cite index="40-5">It will also consider how factors such as age, biology, pregnancy and existing health conditions can influence how women respond to medicines and medical devices.</cite>
The architecture is built around four themes across the product lifecycle. (cite index="38-4,38-5,38-6">Under the data theme, MHRA intends to establish a consistent process for submitting evidence disaggregated by sex throughout the product lifecycle. The programme also proposes guidance, staff training and analytical capacity to assess differences before and after authorisation. It identifies patient-reported outcomes and experiences, real-world data and advanced analysis as potential sources of evidence.</cite>
(cite index="38-7,38-8,38-9">A second strand focuses on technologies serving women's health, often called FemTech. MHRA plans clearer regulatory frameworks and guidance, use cases for existing pathways, and published topics of regulatory interest to encourage earlier engagement. The programme describes these as measures to support innovation while maintaining standards for safety, quality and compliance.</cite>
(cite index="45-5,45-6">The programme covers 2026 to 2030 and falls under the MHRA's Strategy to 2030 priority of proactive regulation to address evidence gaps and reduce inequalities. It is the first part of a wider MHRA initiative on health inequalities.</cite>
FemTech: Big Sector, Thin Rules
(cite index="44-5,44-6">Women's health is a major field for innovation. The UK's FemTech sector already generates nearly £300 million in annual turnover, with technologies being developed across reproductive health, long-term conditions and healthy ageing.</cite>
Industry watchers are cautious. (cite index="41-5,41-6,41-7">David Hill, partner in healthcare and regulation at Browne Jacobson, said the MHRA's Women's Health Programme is a welcome step in plugging these gaps, but it will at some stage need to address a regulatory framework that is struggling to keep pace with FemTech innovation. FemTech covers a wide range of software, diagnostics and apps focused on women's health, and the sector is growing rapidly. Yet regulation of software-based health tools has not kept up with state-of-the-art technology that is advanced enough to actively intervene in a user's health in a manner more akin to physical medical devices.</cite>
That last point matters commercially. The MHRA already issued guidance in July 2026 clarifying which ambient AI scribes qualify as regulated medical devices; a similar line-drawing exercise for FemTech apps that monitor fertility, predict menopause symptoms or flag endometriosis risk is now overdue.
The Trademark Signal
The regulator is not moving alone. AI Business Dispatch analysis of IPO (TMD) data shows 1,157 Class 44 UK trademark filings in Q4 2026, down 48.6% on the prior period. Class 44 covers medical, health and beauty services. A sharp fall in new trademark activity in this class sometimes reflects a market pausing ahead of anticipated regulatory change: firms uncertain how a new framework will classify their product tend to delay branding decisions. The Women's Health Programme, still in its opening phase, may be one reason filings have cooled.
Trademark filings are, however, a lagging and indirect signal. Any direct causal link to the MHRA announcement would be speculative.
Governance and What Comes Next
(cite index="30-6">Patients, researchers, healthcare professionals and industry representatives will all contribute to the programme, which has been shaped with input from the MHRA's Patient and Public Community and a focus group organised by the Patients Association.</cite>
(cite index="36-6">The programme forms part of the MHRA's wider commitment to tackling health inequalities through its recently launched 2030 Strategy and supports the Government's broader ambitions under the renewed Women's Health Strategy for England, alongside corresponding programmes in Scotland, Wales and Northern Ireland.</cite>
(cite index="45-11">The MHRA will host a webinar introducing the programme on 9 December 2026, from 11am to 12pm.</cite> Industry and NHS procurement teams focused on diagnostic AI, reproductive health devices or any software claiming a medical purpose for female patients should treat that webinar as essential listening.
A concurrent development is worth watching. (cite index="21-1,21-2">The NHS has revealed details of a six-figure project through which experts will seek to determine how to monitor the performance and safety of artificial intelligence used to support clinical diagnoses.</cite> (cite index="21-3,21-4,21-5">On 26 November, NHS England intends to enter into a five-month agreement with the Royal College of Radiologists. The professional membership body will be tasked with conducting early-stage research intended to shape AI oversight measures to be implemented in the longer term. The procurement notice describes the work as a discovery project to determine national post-deployment monitoring of AI diagnostic tools in the NHS.</cite>
Taken together, these two moves point to a clear direction for UK health AI regulation in early 2027: more sex-disaggregated evidence at the point of authorisation, and tighter real-world surveillance of AI tools after deployment. For companies building in this space, the window to influence both frameworks is narrow.
